145 related articles for article (PubMed ID: 34855207)
1. Barth syndrome and the many fascinating aspects of cardiolipin.
Vaz FM; Wanders RJA; Vernon H
J Inherit Metab Dis; 2022 Jan; 45(1):1-2. PubMed ID: 34855207
[No Abstract] [Full Text] [Related]
2. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
3. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
4. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
5. Interplay between cardiolipin and plasmalogens in Barth syndrome.
Bozelli JC; Epand RM
J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
[TBL] [Abstract][Full Text] [Related]
6. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.
Garlid AO; Schaffer CT; Kim J; Bhatt H; Guevara-Gonzalez V; Ping P
Gene; 2020 Feb; 726():144148. PubMed ID: 31647997
[TBL] [Abstract][Full Text] [Related]
7. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
8. Loss of protein association causes cardiolipin degradation in Barth syndrome.
Xu Y; Phoon CK; Berno B; D'Souza K; Hoedt E; Zhang G; Neubert TA; Epand RM; Ren M; Schlame M
Nat Chem Biol; 2016 Aug; 12(8):641-7. PubMed ID: 27348092
[TBL] [Abstract][Full Text] [Related]
9. Current and future treatment approaches for Barth syndrome.
Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
[TBL] [Abstract][Full Text] [Related]
10. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
11. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
12. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome.
Gebert N; Joshi AS; Kutik S; Becker T; McKenzie M; Guan XL; Mooga VP; Stroud DA; Kulkarni G; Wenk MR; Rehling P; Meisinger C; Ryan MT; Wiedemann N; Greenberg ML; Pfanner N
Curr Biol; 2009 Dec; 19(24):2133-9. PubMed ID: 19962311
[TBL] [Abstract][Full Text] [Related]
14. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai HM; Hatch GM
Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
[TBL] [Abstract][Full Text] [Related]
15. Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast.
Baile MG; Sathappa M; Lu YW; Pryce E; Whited K; McCaffery JM; Han X; Alder NN; Claypool SM
J Biol Chem; 2014 Jan; 289(3):1768-78. PubMed ID: 24285538
[TBL] [Abstract][Full Text] [Related]
16. Diverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules.
Anzmann AF; Sniezek OL; Pado A; Busa V; Vaz FM; Kreimer SD; DeVine LR; Cole RN; Le A; Kirsch BJ; Claypool SM; Vernon HJ
J Biol Chem; 2021 Sep; 297(3):101005. PubMed ID: 34314685
[TBL] [Abstract][Full Text] [Related]
17. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
18. Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function.
Ye C; Shen Z; Greenberg ML
J Bioenerg Biomembr; 2016 Apr; 48(2):113-23. PubMed ID: 25432572
[TBL] [Abstract][Full Text] [Related]
19. Mechano-energetic aspects of Barth syndrome.
Dudek J; Maack C
J Inherit Metab Dis; 2022 Jan; 45(1):82-98. PubMed ID: 34423473
[TBL] [Abstract][Full Text] [Related]
20. Neurological & psychological aspects of Barth syndrome: Clinical manifestations and potential pathogenic mechanisms.
Olivar-Villanueva M; Ren M; Phoon CKL
Mitochondrion; 2021 Nov; 61():188-195. PubMed ID: 34197965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
